Literature DB >> 26509468

Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism.

F A Klok1,2, O Dzikowska-Diduch3, M Kostrubiec3, H W Vliegen4, P Pruszczyk3, G Hasenfuß5, M V Huisman1, S Konstantinides2, M Lankeit2,5.   

Abstract

UNLABELLED: Essentials Predicting chronic thromboembolic pulmonary hypertension (CTEPH) after pulmonary embolism is hard. We studied 772 patients with pulmonary embolism who were followed for CTEPH (incidence 2.8%). Logistic regression analysis revealed 7 easily collectable clinical variables that combined predict CTEPH. Our score identifies patients at low (0.38%) or higher (10%) risk of CTEPH.
SUMMARY: Introduction Validated risk factors for the diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH) after acute pulmonary embolism (PE) are currently lacking. Methods This is a post hoc patient-level analysis of three large prospective cohorts with a total of 772 consecutive patients with acute PE, without major cardiopulmonary or malignant comorbidities. All underwent echocardiography after a median of 1.5 years. In cases with signs of pulmonary hypertension, additional diagnostic tests to confirm CTEPH were performed. Baseline demographics and clinical characteristics of the acute PE event were included in a multivariable regression analysis. Independent predictors were combined in a clinical prediction score. Results CTEPH was confirmed in 22 patients (2.8%) by right heart catheterization. Unprovoked PE, known hypothyroidism, symptom onset > 2 weeks before PE diagnosis, right ventricular dysfunction on computed tomography or echocardiography, known diabetes mellitus and thrombolytic therapy or embolectomy were independently associated with a CTEPH diagnosis during follow-up. The area under the receiver operating charateristic curve (AUC) of the prediction score including those six variables was 0.89 (95% confidence interval [CI] 0.84-0.94). Sensitivity analysis and bootstrap internal validation confirmed this AUC. Seventy-three per cent of patients were in the low-risk category (CTEPH incidence of 0.38%, 95% CI 0-1.5%) and 27% were in the high-risk category (CTEPH incidence of 10%, 95% CI 6.5-15%). Conclusion The 'CTEPH prediction score' allows for the identification of PE patients with a high risk of CTEPH diagnosis after PE. If externally validated, the score may guide targeting of CTEPH screening to at-risk patients.
© 2015 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  decision support techniques; early diagnosis; prognosis; pulmonary embolism; pulmonary hypertension

Mesh:

Year:  2015        PMID: 26509468     DOI: 10.1111/jth.13175

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  24 in total

Review 1.  Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner
Journal:  Circulation       Date:  2017-01-25       Impact factor: 29.690

Review 2.  Pulmonary hypertension: diagnostic approach and optimal management.

Authors:  Nathan Hambly; Fahad Alawfi; Sanjay Mehta
Journal:  CMAJ       Date:  2016-05-02       Impact factor: 8.262

3.  Massive pulmonary embolism with intra-hospital cardiac arrest and full recovery of right ventricular function after veno-arterial extracorporeal membrane oxygenation therapy: a case report.

Authors:  Stephan Camen; Gerold Söffker; Stefan Kluge; Elvin Zengin
Journal:  Eur Heart J Case Rep       Date:  2020-08-03

Review 4.  Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Krittika Teerapuncharoen; Remzi Bag
Journal:  Lung       Date:  2022-05-29       Impact factor: 2.584

5.  Chronic thromboembolic pulmonary hypertension: anticoagulation and beyond.

Authors:  Karlyn A Martin; Michael J Cuttica
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 6.  Epidemiology and Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension: Risk Factors and Mechanisms.

Authors:  Sarah Medrek; Zeenat Safdar
Journal:  Methodist Debakey Cardiovasc J       Date:  2016 Oct-Dec

7.  Changed hemodynamics in acute vasoreactivity testing: prognostic predictors in chronic thromboembolic pulmonary hypertension.

Authors:  Yan-Zhe Yu; Ping Yuan; Yi-Lan Yang; Yuan-Yuan Sun; Qin-Hua Zhao; Lan Wang; Rong Jiang; Wen-Hui Wu; Jing He; Jing-Hong Dai; Yuan Li; Bigyan Pudasaini; Jin-Ling Li; Su-Gang Gong; Wei-Ping Xie; Jin-Ming Liu
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

8.  Evaluation of the Incidence of Chronic Thromboembolic Pulmonary Hypertension 1 Year After First Episode of Acute Pulmonary Embolism: A Cohort Study.

Authors:  Farid Rashidi; Rezayat Parvizi; Eisa Bilejani; Babak Mahmoodian; Fatemeh Rahimi; Ata Koohi
Journal:  Lung       Date:  2020-01-02       Impact factor: 2.584

9.  Incidence and risk factors of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a systematic review and meta-analysis of cohort studies.

Authors:  Meng Zhang; Ning Wang; Zhenguo Zhai; Mingyuan Zhang; Rongrong Zhou; Yanyan Liu; Yuanhua Yang
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 10.  Treatment of patients with chronic thrombo embolic pulmonary hypertension: focus on riociguat.

Authors:  Zachary R Smith; Charles T Makowski; Rana L Awdish
Journal:  Ther Clin Risk Manag       Date:  2016-06-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.